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Introduction: Tranexamic acid (TXA) is an antifibrinolytic agent currently approved and utilized 
in the treatment of dysfunctional uterine bleeding, traumatic extracranial hemorrhage, anterior 
epistaxis, and dental procedures on patients with hemophilia. There is a paucity of literature 
evaluating the use of TXA for hemostasis in patients on direct oral anticoagulants (DOACs).
Case Report: Our patient, a 72 year-old male on rivaroxaban, presented with persistent bleeding 
following a punch biopsy of the buccal mucosa. Given the site of bleeding, inability to effectively 
tamponade, patient’s anticoagulated state, and risk of impending airway compromise, a dressing was 
soaked with 500 milligram (mg) of TXA and was held in place with pressure using a makeshift clamp 
until a thrombus formed. Hemostasis was achieved preventing the need for acute ENTotolaryngologic 
intervention and/or intubation. The patient was observed in the medical setting overnight and discharged 
home without any recurrence of bleeding or adverse events.
Discussion: This case report describes our experience achieving hemostasis for an otherwise 
uncontrollable oral bleed in an anticoagulated patient on a DOAC who could not be reversed. 
Intervention is simple to perform, cost-effective, and requires few resources which are readily 
available in most emergency departments.
Conclusion: We report a novel application of TXA to control an oral mucosal bleed in an 
anticoagulated patient which was on a DOAC refractory to traditional measures. [Clin Pract Cases 
Emerg Med.2020;4(2):X–X.]
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INTRODUCTION
Tranexamic acid (TXA) is an antifibrinolytic agent 
approved by the Food and Drug Administration for the 
treatment of cyclic, heavy menstrual bleeding and prevention 
of hemorrhage during tooth extractions in patients with 
hemophilia.1 Recently, TXA use has expanded rapidly for a 
variety of off-label indications and is now considered the 
antifibrinolytic of choice in patients who present to the 
emergency department (ED) with extracranial hemorrhage 
following a traumatic injury.2 Further analysis of the 
Yale School of Medicine, Department of Emergency Medicine, New Haven, Connecticut
Yale-New Haven Hospital, Department of Emergency Medicine, New Haven, Connecticut
*
†
CRASH-2 (Corticosteroid Randomization after Significant 
Head Injury) trial demonstrated a significant effect of TXA on 
favorable functional outcomes for the lowest-risk (<6% 
mortality) group. Due to its cost-effectiveness and exceptional 
safety profile TXA is recommended for patients presenting 
within three hours of sustaining a traumatic injury.3 
Atomized nasal TXA with external compression was 
proven to be as effective as standard nasal packing at 
hemostasis, superior at preventing rebleeding events within 
24 hours, and more comfortable than anterior nasal packing 
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What do we already know about this 
clinical entity? 
Tranexamic acid (TXA) clinical 
applications include menstrual bleeding, 
dental extractions, anterior epistaxis, and 
traumatic extracranial hemorrhage.
What makes this presentation of disease 
reportable? 
Emergency department patients on direct 
oral anticoagulants (DOAC) may present 
with bleeding, which is refractory to 
traditional measures.
What is the major learning point? 
TXA was applied topically with no major 
adverse effects to achieve hemostasis of an 
oral bleed in a patient on DOAC who could 
not be reversed.
How might this improve emergency 
medicine practice? 
Further investigation into the use of 
topical TXA as a treatment option for 
refractory hemorrhage in patients on 
DOACs is warranted.
and traditional external compression in managing anterior 
epistaxis.4 The use of TXA, both systemically and topically, 
in the setting of dental extraction and orthognathic surgery 
has been documented in the literature.5 The use of TXA 
suspension-soaked gauze, made from crushed 500 milligram 
(mg) TXA tablets and water, applied directly to the extracted 
cavity to prevent bleeding has been successful in hemophilia 
patients undergoing dental procedures.6 The use of a 0.05% 
TXA irrigation solution following orthognathic surgery and 
5% TXA mouthwash administered after gingival 
manipulation and scaling in patients with hemophilia has 
also been shown to be effective in prevention and/or 
treatment of clinically significant oropharyngeal bleeding.7-8 
It is important to note, however, that each of these 
dosage forms requires manipulation of commercially 
available TXA products, and may not be ideal for urgent use 
in the ED setting. A recent Cochrane Review examined 
randomized controlled trials of people on continuous 
treatment with vitamin K antagonists (VKA) or direct oral 
anticoagulants (DOAC) undergoing oral or dental procedures 
using antifibrinolytic agents to prevent perioperative 
bleeding.9 Although the studies demonstrated a beneficial 
effect of locally applied TXA for patients on continuous 
VKAs, no eligible trials in people on continuous treatment 
with DOACs were identified.
CASE REPORT
A 72 year-old-male with known past medical history 
inclusive of right lower extremity deep vein thrombosis 
currently on the DOAC rivaroxaban, myelodysplastic 
syndrome status post stem cell transplant complicated by graft 
versus host disease (GVHD), hyperlipidemia, stage three 
chronic kidney disease, and type II non-insulin dependent 
diabetes mellitus presented to the ED with right buccal 
mucosa bleed after undergoing punch biopsy by dermatology 
six hours prior. The last administered dose of rivaroxaban was 
earlier the same morning, as he was not instructed to hold the 
dose because the diagnostic punch biopsy for GVHD workup 
was scheduled ad hoc while he was in the hospital for routine 
follow-up. Despite manually holding direct pressure with a 
paper towel over the bleeding site, the patient stated that he 
had been unable to achieve hemostasis, which was affecting 
his ability to speak and sleep due to the continuous need to 
spit out blood, prompting his visit to the ED. A single, folded, 
paper towel sheet became saturated and required exchange 
every 15 minutes. 
Review of systems was notable for oral bleeding, minor 
post-procedural pain (2/10 in severity) at the biopsy site, and 
three days of acute on chronic constipation, believed to be 
unrelated to his chief complaint. The patient denied shortness of 
breath, cough, hemoptysis, and dysphagia. On physical 
examination, the airway was intact, and there was an active, 
continual oozing of dark blood from a five-millimeter biopsy 
site along the right buccal mucosa. Due to the duration of 
bleeding and reported amount of saturated dressings, a complete 
blood count, general chemistry panel, and coagulation panel 
were drawn, which was notable for a hemoglobin and 
Image 1. (a)Tranexamic acid-soaked dressing held in placed with 
tongue depressors and (b) adhesive dressing over patient’s cheek.
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hematocrit of 12.9 grams per deciliter (g/dL) [14-17.4g/dL] and 
37.6% [42-54%], respectively, with prothrombin time and 
international normalized ratio of 10.1 seconds [9.2-11.9 
seconds] and 0.91 [0.8-1.2], respectively. The patient was 
placed in an examination room with continuous wall suctioning 
and given a Yankauer suction tip to clear his oropharynx. 
Given the wide base of the biopsy site and lack of 
overlapping tissue, the wound was not amenable to 
hemostasis through placement of sutures. Thus, along with 
emergency pharmacy guidance and approval, a sterile 
4-inch x 4-inch gauze dressing was soaked with 500 mg [5 
milliliter (mL)] of 100 mg/mL TXA and placed over the 
bleeding site. The soaked gauze was held in place with 
pressure applied by two tongue depressors taped on one 
end with medical tape and held to the patient’s cheek with 
an adhesive dressing (Images 1A and 1B). After 30 
minutes, the device and gauze were removed, and a clot 
was visualized (Image 2). Due to the possibility of 
recurrent bleeding and impending airway compromise, the 
patient was admitted under the otolaryngology service for 
observation and was discharged from the hospital eight 
hours later without any significant rebleeding events. There 
was no 72-hour ED return visit noted within the health 
system’s electronic health records.
DISCUSSION
TXA is a lysine analog similar in chemical structure to 
aminocaproic acid, but with 10 times more potency in its 
affinity to both the strong and weak receptor sites of the 
plasminogen molecule. By competitively binding to 
plasminogen, TXA effectively blocks the conversion of 
plasminogen to plasmin, thereby preventing fibrinolysis 
and, in turn, promotes stabilization of the fibrin clot.10 The 
excellent safety profile of TXA is likely twofold: 
therapeutic doses do not cause platelet aggregation in vitro, 
and when applied topically there is little to no systemic 
absorption. In light of the proposed mechanism and known 
safety profile, we suggest further investigation into the use 
of topical TXA as a potential first-line or adjunctive 
treatment option for difficult to control or refractory 
hemorrhage in particular instances.
CONCLUSION
This case report addresses a novel application of TXA, a 
medication that has become increasingly popular in the ED 
setting to address a very prevalent issue among our 
anticoagulated patient population on DOACs, specifically 
achieving hemostasis that is refractory to more traditional 
measures. We describe our experience achieving hemostasis 
for an otherwise-uncontrollable oral bleeding event in a 
patient whose anticoagulated state could not be reversed. Our 
intervention is simple to perform and cost-effective 
(approximately $21.10 US dollars per 100mg/mL 10mL vial). 
It requires very few resources, which are readily available in 
most EDs and, most importantly, appears effective. We believe 
our methods are widely generalizable and can be easily 
assimilated into the armamentarium of emergency medicine 
providers in a wide range of clinical environments.
Documented patient informed consent has been obtained and 
filed for publication of this case report.
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Image 2. Visualized thrombus over punch biopsy site after being 
treated with pressure dressing soaked in 500 milligrams of 
tranexamic acid  and held in place for 30 minutes.
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